Edition:
India

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.00USD
16 Aug 2019
Change (% chg)

$0.10 (+2.04%)
Prev Close
$4.90
Open
$4.98
Day's High
$5.06
Day's Low
$4.93
Volume
177,622
Avg. Vol
117,880
52-wk High
$6.04
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Pieris Pharmaceuticals Says Cash, Cash Equivalents And Investments Totaled $128.1 Mln As Of Dec 31, 2018
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $128.1 MILLION AS OF DECEMBER 31, 2018.  Full Article

Pieris Pharmaceuticals Q3 Loss Per Share $0.11
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.11.Q3 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.  Full Article

Pieris Pharmaceuticals Inc Files For Mixed Shelf Of Upto $200 Mln
Friday, 10 Aug 2018 

Aug 9 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.  Full Article

Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Pieris Pharmaceuticals Inc ::SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL PAY PIERIS A $30 MILLION UPFRONT FEE, TIERED ROYALTIES ON NET SALES UP TO LOW DOUBLE-DIGITS​.SEATTLE GENETICS - CO, PIERIS TO EVALUATE BISPECIFIC IMMUNO-ONCOLOGY AGENTS COMBINING PIERIS' ANTICALIN TECHNOLOGY WITH SOME OF CO'S CANCER-TARGETED ANTIBODIES.SEATTLE GENETICS - UNDER TERMS OF AGREEMENT CO TO PAY PIERIS UP TO $1.2 BILLION IN TOTAL SUCCESS-BASED PAYMENTS ACROSS THREE PRODUCT CANDIDATES.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL SOLELY DEVELOP, FUND AND COMMERCIALIZE OTHER TWO PROGRAMS​.SEATTLE GENETICS-PIERIS PHARMA, CO HAVE ENTERED INTO AGREEMENT FOR DEVELOPING MULTIPLE TARGETED BISPECIFIC IMMUNO-ONCOLOGY TREATMENTS FOR BLOOD CANCERS.SEATTLE GENETICS INC - ‍PRIOR TO INITIATION OF A PIVOTAL TRIAL, PIERIS MAY OPT INTO GLOBAL CO-DEVELOPMENT AND U.S. COMMERCIALIZATION OF SECOND PROGRAM​.SEATTLE GENETICS - PRIOR TO INITIATION OF PIVOTAL TRIAL, PIERIS MAY OPT FOR A SHARE IN GLOBAL COSTS, PROFITS ON 50/50 BASIS FOR SECOND PROGRAM.  Full Article

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors.Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​.  Full Article

Pieris Pharmaceuticals reports Q3 loss per share $0.16
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update.Q3 loss per share $0.16.Pieris Pharmaceuticals Inc - ‍cash and equivalents totaled $89.9 million as of September 30, 2017, compared to $29.4 million as of December 31, 2016​.  Full Article